<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805257</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#16-18935</org_study_id>
    <nct_id>NCT02805257</nct_id>
  </id_info>
  <brief_title>Ahmed Glaucoma Valve Surgery With Mitomycin-C</brief_title>
  <acronym>AMCT</acronym>
  <official_title>Ahmed Glaucoma Valve Surgery With Mitomycin-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bascom Palmer Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Central Militar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shri Ganesh Vinayak Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of Mitomycin-C use in the glaucoma surgery Ahmed&#xD;
      valve implantation. Approximately 100 patients will be enrolled, with half receiving the&#xD;
      Mitomycin-C treatment and the other half receiving placebo treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is a leading cause irreversible blindness worldwide. Glaucoma valve surgeries such&#xD;
      as Ahmed valve implantation, which are conventional surgeries performed to control&#xD;
      intraocular pressure in eyes, are sometimes associated with complications due to fibrosis.&#xD;
      Mitomycin-C is a commonly used antifibrotic agent used in glaucoma surgeries. This study will&#xD;
      evaluate the effectiveness of Mitomycin-C injections intraoperatively and postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure after surgery</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure after surgery</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medications postoperatively</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell count</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell count</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Glaucoma</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Secondary Glaucoma</condition>
  <condition>Neovascular Glaucoma</condition>
  <arm_group>
    <arm_group_label>Mitomycin-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Balanced Salt Solution (BSS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C</intervention_name>
    <description>Intraoperative and postoperative injections of mitomycin-c/Mitosol</description>
    <arm_group_label>Mitomycin-C</arm_group_label>
    <other_name>Mitosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Balanced Salt Solution</intervention_name>
    <description>Intraoperative and postoperative injections of BSS</description>
    <arm_group_label>Balanced Salt Solution (BSS)</arm_group_label>
    <other_name>BSS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ahmed Glaucoma Valve Implant</intervention_name>
    <description>Implantation of Ahmed Valve in study eye</description>
    <arm_group_label>Balanced Salt Solution (BSS)</arm_group_label>
    <arm_group_label>Mitomycin-C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inadequately controlled glaucoma on maximum tolerated medical therapy with intraocular&#xD;
             pressure (IOP) greater than or equal to 18 mm Hg.&#xD;
&#xD;
          -  Ahmed Glaucoma Valve (AGV) implantation as the planned surgical procedure.&#xD;
&#xD;
          -  For patients in whom 2 eyes are eligible for enrollment, only the first eligible eye&#xD;
             to be implanted is enrolled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to give consent, unwilling to accept randomization, or unable to&#xD;
             return for scheduled protocol visits.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Previous cyclodestruction or glaucoma drainage device (GDD) surgery.&#xD;
&#xD;
          -  Patients with nanophthalmos.&#xD;
&#xD;
          -  Patients with Sturge-Weber syndrome or other conditions associated with elevated&#xD;
             episcleral venous pressure.&#xD;
&#xD;
          -  No light perception vision.&#xD;
&#xD;
          -  VA &lt;20/200 in non-study eye.&#xD;
&#xD;
          -  Need for glaucoma surgery combined with other ocular procedures (i.e. cataract&#xD;
             extraction, penetrating keratoplasty, or retinal surgery) or anticipated need for&#xD;
             additional ocular surgery.&#xD;
&#xD;
          -  Previous scleral buckling procedure or silicone oil present.&#xD;
&#xD;
          -  Uveitic glaucoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Han, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shri Ganesh Vinayak Eye Hospital</name>
      <address>
        <city>Raipur</city>
        <state>Chhattisgarh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México (APEC)</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <disposition_first_submitted>February 25, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>April 27, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 30, 2021</disposition_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plans to share IPD to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

